journal article·2026-04Open access

Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis

Huanqing Zhu, Haonan Yu, Mengxin Huang, Panjie Sun, Yuanfang Tang, Zhanyi Zhang, Puming He, Youying Tu, Bo Li

Abstract

Atopic dermatitis (AD) is an inflammatory skin disease characterized by a complex pathogenesis. Current clinical treatments exhibit several limitations, including low efficacy and considerable side effects, prompting a growing interest in novel therapeutic strategies. In this study, we developed a microneedle-assisted dual-nano drug delivery strategy that targets both oxidative stress and Janus kinase 1 (JAK1) expression, aiming for enhanced therapy of AD. Self-assembling nanoparticles (NPs) incorporating epigallocatechin gallate (EGCG) and lactoferrin were developed to effectively modulate oxidative stress. Concurrently, CRISPR-CasRx technology was employed to silence JAK1, and nanoparticles were constructed by encapsulating CasRx and siRNA within poly (β-amino ester) (PBAE). Both types of NPs were successfully delivered to skin lesions in AD mice through microneedles, either individually or combined, resulting in significant alleviation of symptoms. Treatment reduced dermatitis severity scores and splenomegaly, decreased epidermal thickness and mast cell infiltration, and increased collagen fiber content. Additionally, levels of inflammatory cytokines (IL-1β, IL-4, IL-13) and oxidative DNA damage marker (8-OHdG) in dorsal skin tissues were lowered, accompanied by decreased serum levels of thymic stromal lymphopoietin (TSLP) and IgE. The therapy also suppressed JAK1 expression and activated the Nuclear factor erythroid 2-related factor 2 (Nrf2) / Heme oxygenase 1‌ (HO-1) antioxidant pathway, except for PBAE-plasmid NP-loaded microneedles, which did not significantly increase HO-1 expression. Notably, microneedles containing both NPs exhibited superior efficacy in reducing IL-1β and JAK1 levels and upregulating Nrf2 expression compared to formulations with only one NP type. This innovative combination strategy demonstrates promise as a novel therapeutic approach for AD. • EGCG-lactoferrin and PBAE-plasmid NPs for JAK1 silencing via CasRx was developed • Microneedles containing either a single or both NPs alleviated atopic dermatitis • Microneedle treatment reduced inflammation and oxidative stress in mice with AD • Microneedle therapy modulated the JAK1 and Nrf2/HO-1 pathways in mice with AD • Microneedles with both NPs showed greater efficacy than those with a single NP
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dermatology and Skin Diseases · Advancements in Transdermal Drug Delivery · Psoriasis: Treatment and Pathogenesis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (87)

Show source-provided references
1. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease10.1038/s41573-021-00266-6 ↗
2. Extract alleviates atopy-like lesions in NC/Nga mice via inhibition of the JAK1-STAT1/3 pathway10.1016/j.biopha.2023.115903 ↗
3. Atopic dermatitis10.1038/s41572-018-0001-z ↗
4. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review10.3389/fimmu.2022.1068260 ↗
5. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib10.1007/s40257-020-00548-6 ↗
6. JAK inhibitors in the treatment of atopic dermatitis10.1016/j.jaci.2021.08.009 ↗
7. Emerging therapies for atopic dermatitis: JAK inhibitors10.1016/j.jaad.2017.12.019 ↗
8. The safety of systemic janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials10.1111/jdv.19426 ↗
9. Next-generation CRISPR-based gene-editing therapies tested in clinical trials10.1038/d41591-024-00056-8 ↗
10. Engineered extracellular vesicle-delivered CRISPR/CasRx as a novel RNA editing tool10.1002/advs.202206517 ↗
11. RNA-targeting CRISPR/CasRx system relieves disease symptoms in Huntington'S disease models10.1186/s13024-024-00794-w ↗
12. Current and future status of JAK inhibitors10.1016/S0140-6736(21)00438-4 ↗
13. Hydrogel-based treatment of house dust mite-induced atopic dermatitis through triple cleaning of mites, bacteria, and ROS-related inflammation10.1021/acsami.4c05435 ↗
14. Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitis10.1038/s41467-023-38209-x ↗
15. Antioxidant effects of catechins (EGCG), andrographolide, and curcuminoids compounds for skin protection, cosmetics, and dermatological uses: an update10.3390/antiox12071317 ↗
16. Epigallocatechin-3-gallate improves extract-induced atopic dermatitis-like skin lesions in NC/Nga mice by suppressing macrophage migration inhibitory factor10.1016/j.intimp.2008.04.002 ↗
17. Nanochemoprevention with therapeutic benefits: an updated review focused on epigallocatechin gallate delivery10.1080/10408398.2019.1565490 ↗
18. Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy10.1016/j.addr.2024.115198 ↗
19. Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand10.1016/j.biomaterials.2020.120355 ↗
20. Nose-to-brain delivery of self-assembled curcumin-lactoferrin nanoparticles: characterization, neuroprotective effect and pharmacokinetic study
21. Effects of ultrasound and thermal treatment on the interaction between hyaluronic scid and lactoferrin: preparation, structures and functionalities10.1016/j.ijbiomac.2024.132812 ↗
22. Hydrogel microneedle arrays for transdermal drug delivery10.1007/BF03353783 ↗
23. Gene delivery to the skin - how far have we come? Trends
24. Massively parallel cas13 screens reveal principles for guide RNA design10.1038/s41587-020-0456-9 ↗
25. Genome-editing prodrug: targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease10.1126/sciadv.abj0624 ↗
26. Co-encapsulation of (-)-epigallocatechin-3-gallate and piceatannol/oxyresveratrol in β-lactoglobulin: effect of ligand-protein binding on the antioxidant activity, stability, solubility and cytotoxicity10.1039/D1FO00481F ↗
27. The multifaceted roles of bovine lactoferrin: molecular structure, isolation methods, analytical characteristics, and biological properties10.1021/acs.jafc.3c06887 ↗
28. Recent development of lactoferrin-based vehicles for the delivery of bioactive compounds: complexes, emulsions, and nanoparticles10.1016/j.tifs.2018.06.013 ↗
29. Lactoferrin-polyphenol composite nanocoating with enhanced chemical stability and cell-compatibility10.1016/j.porgcoat.2023.108099 ↗
30. Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity10.1016/j.neuint.2016.01.006 ↗
31. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery10.3109/10717544.2013.766781 ↗
32. Preservation of (-)-epigallocatechin-3-gallate antioxidant properties loaded in heat treated β-lactoglobulin nanoparticles10.1021/jf300307t ↗
33. Chijabyukpi-tang inhibits pro-inflammatory cytokines and chemokines the Nrf2/HO-1 signaling pathway in TNF-α/IFN-γ-stimulated HaCaT cells and ameliorates 2,4-dinitrochlorobenzene-Induced atopic dermatitis-like skin lesions in mice10.3389/fphar.2020.01018 ↗
34. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles10.1016/j.biomaterials.2011.06.073 ↗
35. Encapsulation of polyphenols in protein-based nanoparticles: preparation, properties, and applications10.1080/10408398.2023.2237126 ↗
36. Therapeutic hydrogel patch to treat atopic dermatitis by regulating oxidative stress10.1021/acs.nanolett.1c04899 ↗
37. Enhancing the effects of curcumin on oxidative stress injury in brain vascular endothelial cells using lactoferrin peptide nano-micelles: antioxidant activity and mechanism10.1002/jsfa.13836 ↗
38. Nanoparticle impregnated self-supporting protein gel for enhanced reduction in oxidative stress: a molecular dynamics insight for lactoferrin-polyphenol interaction10.1016/j.ijbiomac.2021.08.089 ↗
39. Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways10.1080/17435889.2025.2462521 ↗
40. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial10.1016/S0140-6736(22)01199-0 ↗
41. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors10.1016/j.cell.2018.02.033 ↗
42. An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (β-amino ester) nanoparticles for vaginal gene therapy10.1016/j.ebiom.2020.102897 ↗
43. JAK inhibitors: is specificity at all relevant?10.1016/j.semarthrit.2023.152327 ↗
44. Microneedles as an emerging platform for transdermal delivery of phytochemicals10.1021/acs.molpharmaceut.4c00894 ↗
45. Microneedle-assisted genome editing: a transdermal dtrategy of targeting by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders10.1126/sciadv.abe2888 ↗
46. Microneedle-mediated nose-to-brain drug delivery for improved Alzheimer'S disease treatment10.1016/j.jconrel.2024.01.013 ↗
47. Role of skin-homing t-cells in recurrent episodes of atopic dermatitis: a review
48. Therapeutic effects of Sigesbeckia pubescens Makino against atopic dermatitis-like skin inflammation through the JAK2/STAT signaling pathway10.3390/ijms26094191 ↗
49. Hyaluronic acid based microneedle array: recent applications in drug delivery and cosmetology10.1016/j.carbpol.2021.118168 ↗
50. Effect of hyaluronic acid initial concentration on cross-linking efficiency of hyaluronic acid-based hydrogels used in biomedical and cosmetic applications
51. Cellular uptake of nanoparticles: journey inside the cell10.1039/C6CS00636A ↗
52. Cellular uptake of nanoparticles versus small molecules: a matter of size10.1021/acs.accounts.8b00292 ↗
53. Physicochemical and surface properties of nanoparticles: effects on cellular pathway and uptake10.1002/cnma.202500043 ↗
54. The contribution of mouse models to understanding atopic dermatitis10.1016/j.bcp.2022.115177 ↗
55. Comparative analysis of mediastinal fat-associated lymphoid cluster development and lung cellular infiltration in murine autoimmune disease models and the corresponding normal control strains10.1111/imm.12539 ↗
56. Mechanistic evaluation of EGCG against atopic dermatitis: an and study
57. Superoxide dismutase-mimetic polyphenol-based carbon dots for multimodal bioimaging and treatment of atopic dermatitis10.1021/acsami.4c02634 ↗
58. Topical janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: a case series10.1016/j.jaad.2022.03.012 ↗
59. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies10.1016/j.jaad.2021.04.085 ↗
60. Mast cells enhance T cell activation: importance of mast cell-derived TNF10.1073/pnas.0501912102 ↗
61. Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects10.2147/IJN.S212260 ↗
62. Unraveling the ECM-immune cell crosstalk in skin diseases10.3389/fcell.2019.00068 ↗
63. Jiu-Wei-Yong-an formula suppresses JAK1/STAT3 and MAPK signaling alleviates atopic dermatitis-like skin lesions
64. Update on the pathogenesis and therapy of atopic dermatitis10.1007/s12016-021-08880-3 ↗
65. Allergy inhibition using naturally occurring compounds targeting thymic stromal lymphopoietin pathways: a comprehensive review10.4062/biomolther.2024.177 ↗
66. Atopic dermatitis: pathogenesis and therapeutic intervention10.1002/mco2.70029 ↗
67. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies10.1016/j.alit.2016.12.002 ↗
68. IL-1β induces thymic stromal lymphopoietin and an atopic dermatitis-like phenotype in reconstructed healthy human epidermis10.1002/path.4887 ↗
69. Topical application of JAK1/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice10.3390/ijms19123973 ↗
70. The JAK/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review10.3390/jcm11154431 ↗
71. N-heterocyclic functionalized chalcone derivatives as anti-inflammatory agents for atopic dermatitis treatment by inhibiting JAK1/STAT3 signaling pathway10.1016/j.bioorg.2025.108200 ↗
72. EGCG inhibits tumor growth in melanoma by targeting JAK-STAT signaling and its downstream PD-L1/PD-L2-PD1 axis in tumors and enhancing cytotoxic T-cell responses10.3390/ph14111081 ↗
73. 8-Hydroxydeoxyguanosine in urine as an index of oxidative damage to DNA in the evaluation of atopic dermatitis10.1046/j.1365-2133.1998.02273.x ↗
74. The protective effect of polyherbal formulation, harak formula, on UVA-induced photoaging of human dermal fibroblasts and mouse skin promoting Nrf2-regulated antioxidant defense10.3389/fphar.2021.649820 ↗
75. Histone deacetylase 3 inhibition alleviates 2,4-dinitrochlorobenzene-in-duced atopic dermatitis via epigenetically upregulating Nrf2/HO-1 signaling pathway10.1016/j.intimp.2023.111107 ↗
76. Epigallocatechin-3-gallate attenuates microcystin-LR-induced apoptosis in human umbilical vein endothelial cells through activation of the NRF2/HO-1 pathway10.1016/j.envpol.2018.04.038 ↗
77. Protective effects of epigallocatechin gallate against ischemia reperfusion injury in rat skeletal muscle via activating Nrf2/HO-1 signaling pathway10.1016/j.lfs.2019.117014 ↗
78. Heme oxgenase-1, a cardinal modulator of regulated cell death and inflammation10.3390/cells10030515 ↗
79. Regulation of the expression of heme oxygenase-1:Signal transduction, gene promoter activation, and beyond10.1089/ars.2019.7991 ↗
80. The significance of precisely regulating heme oxygenase-1 expression: another avenue for treating age-related ocular disease?10.1016/j.arr.2024.102308 ↗
81. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model10.1111/j.1365-2249.2004.02649.x ↗
82. The effect of topically applied corticosteroids on interleukin 1β levels in patients with atopic dermatitis10.1111/j.1468-3083.2011.04133.x ↗
83. The role of NRF2 transcription factor in inflammatory skin diseases10.1002/biof.70013 ↗
84. Quantitative proteomics identifies reduced NRF2 activity and mitochondrial dysfunction in atopic dermatitis10.1016/j.jid.2022.08.048 ↗
85. Precise PBAEs: a highly efficient single-molecularly defined gene-delivery system10.1002/anie.202422134 ↗
86. Circular vectors as an efficient, fully synthetic, cell-free approach for preparing small circular DNA as a plasmid substitute for guide RNA expression in CRISPR-Cas9 genome editing10.1038/s41596-024-01138-0 ↗
87. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications10.1016/j.biomaterials.2022.121876 ↗